INS and type 2 diabetes mellitus: As demonstrated by ONWARDS findings, insulin icodec showed a comparable clinical efficacy profile with basal insulin analogues, in both T1DM and T2DM patients, regardless of whether patients had previously been treated with basal insulin or not.